Shares of Alkermes PLC (NASDAQ:ALKS) opened at 55.11 on Monday. Alkermes PLC has a 52-week low of $27.14 and a 52-week high of $60.74. The company’s 50 day moving average price is $55.85 and its 200 day moving average price is $51.84. The stock’s market capitalization is $8.38 billion.
Alkermes PLC (NASDAQ:ALKS) is scheduled to be announcing its Q416 earnings results on Wednesday, February 15th. Analysts expect the company to announce earnings of $0.04 per share and revenue of $206.38 million for the quarter. Investors that are interested in registering for the company’s conference call can do so using this link.
In related news, Director Richard F. Pops sold 30,000 shares of the company’s stock in a transaction dated Tuesday, November 22nd. The stock was sold at an average price of $58.66, for a total transaction of $1,759,800.00. Following the transaction, the director now directly owns 638,962 shares of the company’s stock, valued at approximately $37,481,510.92. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CMO Elliot Ehrich sold 11,983 shares of the company’s stock in a transaction dated Tuesday, January 17th. The shares were sold at an average price of $54.32, for a total value of $650,916.56. Following the transaction, the chief marketing officer now directly owns 62,640 shares in the company, valued at $3,402,604.80. The disclosure for this sale can be found here. Insiders have sold a total of 242,800 shares of company stock worth $13,827,583 over the last ninety days. 4.75% of the stock is currently owned by corporate insiders.
ALKS has been the subject of a number of research analyst reports. Zacks Investment Research raised Alkermes PLC from a “sell” rating to a “hold” rating in a research report on Tuesday, December 13th. Cantor Fitzgerald initiated coverage on Alkermes PLC in a research report on Thursday, December 15th. They set a “neutral” rating and a $52.00 target price for the company. Jefferies Group LLC lifted their target price on Alkermes PLC from $62.00 to $70.00 and gave the company a “buy” rating in a research report on Friday, October 21st. Morgan Stanley raised Alkermes PLC from an “underweight” rating to a “hold” rating and set a $62.00 target price for the company in a research report on Friday, October 21st. Finally, J P Morgan Chase & Co raised Alkermes PLC from a “neutral” rating to an “overweight” rating and lifted their target price for the company from $51.00 to $78.00 in a research report on Friday, October 21st. Four research analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average target price of $60.83.
About Alkermes PLC
Alkermes Public Limited Company is a biopharmaceutical company. The Company is engaged in researching, developing and commercializing, both with partners and on its own, pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. The Company has a portfolio of approximately 20 products and a clinical pipeline of product candidates that address central nervous system (CNS) disorders, such as schizophrenia, depression, addiction and multiple sclerosis.